A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
CNBC
The brief
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Reported by
CNBC
This is a short headline brief. The complete report belongs to its publisher.
